Every published free trial to paid conversion benchmark traces back to the same three or four sources. They all report the same medians, the same quartiles, the same caveat about opt-in vs opt-out — and none of them answer the question that actually predicts conversion: which in-product actions during the trial separate converters from non-converters? This article adds the activation milestone framework that's missing from every benchmark report.
What is a good free trial to paid conversion rate for SaaS?
The median free trial to paid conversion rate depends almost entirely on trial model. Opt-in trials (no credit card required) convert at 3–5%. Opt-out trials (card upfront) convert at 15–25%. Freemium models convert at 2–5%. These numbers are remarkably stable across sources — Totango, Recurly, OpenView, and Lenny Rachitsky all land within the same band.
Top-quartile performance roughly doubles the median in each category: 8–10% for opt-in, 30%+ for opt-out, 7–10% for freemium. A fourth model — the reverse trial, where users get the full product temporarily before dropping to a free tier — sits between opt-in and opt-out at 8–15% median.
Trial-to-Paid Conversion
Percentage of trial users who convert to a paid subscription.
These ranges are genuine. The problem is not that the benchmarks are wrong. The problem is that a single number — "our trial converts at 7%" — collapses so many variables that it tells you almost nothing about what to fix.
Why the headline number is almost useless
A 7% opt-in conversion rate could be excellent or terrible depending on three factors that the headline number hides. Each one shifts the expected range by 2–5x, which means two companies reporting identical conversion rates can have fundamentally different trial health.
Opt-in vs opt-out trial models
This is the largest single variable. Opt-out trials (card upfront) convert at 3–5x the rate of opt-in trials because they select for higher intent at signup — someone willing to enter a credit card is already closer to buying. The tradeoff is volume: opt-in trials generate 2–4x more signups. Companies switching from opt-in to opt-out typically see conversion rates jump from ~5% to ~20% while total trial starts drop by half.
The math often nets out similarly. 10,000 opt-in trials at 5% = 500 conversions. 5,000 opt-out trials at 20% = 1,000 conversions. But the quality of the converted cohort differs — opt-out converters include a meaningful percentage who forgot to cancel, leading to higher early churn. The true comparison requires tracking 90-day retention post-conversion, not just the conversion event.
Trial length
Shorter trials convert at higher rates, counterintuitively. A 7-day trial typically converts 10–20% better than a 14-day trial for the same product because urgency compresses the evaluation window. The user either reaches the value threshold quickly or abandons — there's less time to go dormant mid-trial and never return.
Longer trials (30 days) show the lowest conversion rates but the highest post-conversion retention, because users who convert after 30 days of evaluation have thoroughly validated the product. The right trial length depends on product complexity: a simple tool can demonstrate value in 7 days; an analytics platform that needs a month of data ingestion can't.
B2B vs B2C, low-touch vs high-touch
B2B trials with a sales touch convert at 2–3x the rate of self-serve trials. A product-led B2B company seeing 5% opt-in conversion is performing at median; a sales-assisted company seeing 5% has a problem. B2C trials skew lower overall because the average revenue per account is smaller, so the willingness to enter payment details is lower.
ACV matters within B2B too. Products above $500/mo ACV typically see lower trial conversion rates but higher per-conversion revenue. The decision involves more stakeholders, longer evaluation cycles, and procurement friction that a self-serve trial can't bypass. Comparing a $29/mo tool's 12% conversion to a $2,000/mo platform's 4% conversion is comparing different sports.
Trial-to-paid benchmarks by model and segment
The following benchmarks segment by the three variables that actually matter: trial model, ACV tier, and trial duration. Use the row that matches your setup — not the single-number average that blends all three.
By trial type
| Trial Model | Median Conversion | Top Quartile | Key Variable |
|---|---|---|---|
| Opt-in (no card) | 3–5% | 8–10% | Activation depth |
| Opt-out (card upfront) | 15–25% | 30%+ | Value before trial end |
| Freemium | 2–5% | 7–10% | Feature gating |
| Reverse trial | 8–15% | 20%+ | Loss aversion timing |
The "Key Variable" column is the lever that separates median from top quartile within each model. Opt-in trials live and die by activation depth — how many users reach a meaningful usage milestone before the trial expires. Opt-out trials depend on delivering enough value before the trial end that cancellation feels like a loss, not a relief.
By ACV tier
Low-ACV products ($0–$50/mo) see the highest raw conversion rates: 10–15% on opt-in trials because the purchase decision is impulsive. The friction is low enough that users convert without a formal evaluation. Mid-ACV ($50–$500/mo) drops to 5–8% as the decision involves a budget holder. High-ACV ($500+/mo) drops further to 2–5% as procurement, security review, and multi-stakeholder approval enter the process.
The inverse holds for revenue per trial start. A high-ACV product converting 3% of trials at $1,000/mo generates $30 MRR per trial start. A low-ACV product converting 12% at $29/mo generates $3.48. Optimizing for conversion rate without accounting for revenue per conversion is optimizing the wrong metric.
By trial duration
7-day trials convert 15–25% higher than 14-day trials and 30–40% higher than 30-day trials, holding all else equal. But the metric that matters is revenue per trial start, not conversion rate. A 30-day trial that converts at 4% but retains 85% at month 3 outperforms a 7-day trial that converts at 7% but retains 60%.
The pattern: shorter trials optimize for conversion rate; longer trials optimize for post-conversion retention. The right choice depends on whether your funnel is starved for conversions or leaking post-conversion. Most companies below $2M ARR are conversion-starved; most above $10M ARR are retention-focused.
The activation milestone framework
Trial conversion rate is a lagging indicator. By the time you measure it, the trial is over and the user has either paid or churned. Activation milestones are leading indicators — in-product behaviors during the trial that predict whether the user will convert. Improving activation milestone completion rates is how you improve trial conversion without changing the trial model itself.
Identifying your "aha moment" from billing data patterns
The standard advice is to find your product's "aha moment" through product analytics — event tracking, cohort analysis, behavioral segmentation. That works if you have a product analytics stack. But billing data alone reveals a surprisingly strong signal.
Pull every trial that converted in the last 12 months and measure the time from trial start to first meaningful action (first project created, first integration connected, first report generated). Then pull every trial that didn't convert and measure the same thing. The distribution gap between those two groups identifies your activation threshold. Converters almost always hit the milestone earlier — often within the first 48 hours.
The billing data shortcut: compare the subscription start date to the trial start date. If converters consistently activate the subscription before the trial end date (early conversion), your trial is longer than it needs to be. If converters consistently activate on the last day (deadline conversion), the trial length is well-calibrated but you're leaving the "dormant middle" unaddressed.
The 3-milestone framework
Rather than tracking a single "aha moment," the most predictive approach tracks three sequential milestones during the trial period. Each milestone has a different conversion correlation and requires a different intervention when users stall.
Milestone 1: Setup completion— the user finishes initial configuration (connects a data source, invites a team member, completes onboarding). Benchmark: 60–70% of trial starts should hit this within 24 hours. Users who don't complete setup within 48 hours convert at less than 1%.
Milestone 2: Value event — the user experiences the core product value for the first time (runs their first report, sends their first campaign, processes their first transaction). Benchmark: 40–50% of trial starts. The gap between Milestone 1 and Milestone 2 is where most trials die — the user set it up but never did the thing the product exists to do.
Milestone 3: Habit formation — the user returns and performs the value event a second or third time. Benchmark: 20–30% of trial starts. Users who reach Milestone 3 convert at 50–70%, regardless of trial model. This is the true leading indicator of conversion — not whether someone signed up, but whether they came back.
The 3-milestone framework turns trial optimization from a post-hoc analysis ("why was conversion low last month?") into a real-time operating system ("40% of this week's trials stalled between Milestone 1 and 2 — trigger the onboarding email sequence"). The milestone where users stall tells you what to fix: stalling at setup is a UX problem; stalling at the value event is a product-market fit signal; stalling at habit formation is a retention problem.
Measuring trial conversion from billing data
Most trial conversion analysis requires a product analytics stack — event tracking, funnel visualization, cohort segmentation. But the conversion event itself lives in billing data: a trial subscription transitioning to an active paid subscription in Stripe.
Monthly Recurring Revenue
Predictable monthly revenue from active subscriptions, normalized from all billing intervals.
North Metric computes trial-to-paid conversion directly from connected Stripe accounts. Every trial start, trial end, and conversion event is captured with its timestamp and dollar amount. The conversion rate is segmented automatically by trial duration, plan tier, and cohort month — so the number you see is the number that applies to your specific trial model, not a blended average across configurations you don't run.
For portfolio investors, the same computation runs across every connected company. Trial conversion becomes a comparable metric — not because every company runs the same trial model, but because each company's rate is benchmarked against the correct segment. A 4% opt-in conversion is median; a 4% opt-out conversion is a red flag. The segmented benchmark is the context that makes the number useful.